Organon Total Other Income Expense Net Over Time

OGN Stock  USD 15.36  0.30  1.92%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Organon Performance and Organon Correlation.
  
As of the 4th of December 2024, Total Other Income Expense Net is likely to grow to about (623.2 M).
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organon. If investors know Organon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
5.081
Dividend Share
1.12
Earnings Share
5.05
Revenue Per Share
24.984
Quarterly Revenue Growth
0.041
The market value of Organon is measured differently than its book value, which is the value of Organon that is recorded on the company's balance sheet. Investors also form their own opinion of Organon's value that differs from its market value or its book value, called intrinsic value, which is Organon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organon's market value can be influenced by many factors that don't directly affect Organon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Organon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Total Other Income Expense Net Analysis

Compare Organon and related stocks such as Crinetics Pharmaceuticals, Enanta Pharmaceuticals, and Amicus Therapeutics Total Other Income Expense Net Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
CRNX(1000)(1000)(1000)(1000)(1000)(1000)(1000)(48 K)1.6 M3.4 M1.1 M61 KM8.1 M8.5 M
ENTA791 K(8 K)598 K283 K1.3 M1.7 M2.3 M4.8 M8.8 M6.6 MM1.7 M6.2 M3.9 M3.1 M
FOLD(168 K)2.8 M674 K(1.1 M)(114 K)(5.4 M)(24.9 M)(225.1 M)(11.7 M)(55.2 M)(30.4 M)(41.6 M)(37.6 M)(76.6 M)(72.8 M)
CNTB(58.4 M)(58.4 M)(58.4 M)(58.4 M)(58.4 M)(58.4 M)(58.4 M)(58.4 M)(58.4 M)(58.4 M)(89.1 M)(103.2 M)(403.7 K)2.7 M2.8 M
LGND(5.5 M)(50 K)(4.8 M)(6.8 M)(9.4 M)M(37 M)(10.8 M)43.9 M802.4 M(36.4 M)(31.6 M)33 M51.7 M54.3 M
PASG(2.7 M)(2.7 M)(2.7 M)(2.7 M)(2.7 M)(2.7 M)(2.7 M)(2.7 M)(2.7 M)(8.4 M)670 K343 K2.3 M6.3 M6.6 M
ORIC233 K233 K233 K233 K233 K233 K233 K233 K233 K1.7 M483 K156 K2.6 M10.1 M10.6 M
LYEL(27.3 M)(27.3 M)(27.3 M)(27.3 M)(27.3 M)(27.3 M)(27.3 M)(27.3 M)(27.3 M)(27.3 M)7.5 M(36.7 M)3.8 M12.4 M13 M
DSGN(139 K)(139 K)(139 K)(139 K)(139 K)(139 K)(139 K)(139 K)(139 K)(139 K)50 K298 K4.3 M11.3 M11.9 M
RVMDKKKKKKKK(2.1 M)2.1 M2.2 M917 K9.2 M47.3 M49.7 M

Organon and related stocks such as Crinetics Pharmaceuticals, Enanta Pharmaceuticals, and Amicus Therapeutics Total Other Income Expense Net description

My Equities

My Current Equities and Potential Positions

Organon Co
OGN
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationNew Jersey; U.S.A
ExchangeNew York Stock Exchange
USD 15.36
When determining whether Organon offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Organon's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organon Co Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organon Co Stock:
Check out Organon Performance and Organon Correlation.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Organon technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Organon technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Organon trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...